These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10498468)

  • 41. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
    Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
    Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ganciclovir in the treatment of cytomegalovirus pneumonitis in bone marrow transplant recipients.
    Milliken S; Powles R; Ettinger N; Gallagher C; Jameson B; Tryhorn Y; Stern H; Selby P
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3110-1. PubMed ID: 2539692
    [No Abstract]   [Full Text] [Related]  

  • 46. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis.
    Couchoud C; Cucherat M; Haugh M; Pouteil-Noble C
    Transplantation; 1998 Mar; 65(5):641-7. PubMed ID: 9521197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
    Reischig T
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of cytomegalovirus disease in transplant recipients.
    Winston DJ
    Lancet; 1995 Nov; 346(8987):1380-1. PubMed ID: 7475816
    [No Abstract]   [Full Text] [Related]  

  • 50. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
    Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
    Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.
    Cantarovich M; Hiesse C; Lantz O; Fassi-Fihri S; Charpentier B; Fries D
    Transplantation; 1988 Jun; 45(6):1139-41. PubMed ID: 2837848
    [No Abstract]   [Full Text] [Related]  

  • 52. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).
    Bell WR; Chulay JD; Feinberg JE
    Medicine (Baltimore); 1997 Sep; 76(5):369-80. PubMed ID: 9352739
    [No Abstract]   [Full Text] [Related]  

  • 53. Cytomegalovirus infection and renal transplantation.
    Metselaar HJ; Weimar W
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():37-47. PubMed ID: 2550411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylaxis and treatment of CMV infections in transplantation.
    Zaia JA
    Adv Exp Med Biol; 1996; 394():117-34. PubMed ID: 8815679
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of 9-(2-hydroxy-1-[hydroxymethyl] ethoxymethyl) guanine (DHPG) on cytomegalovirus pneumonitis after renal transplantation.
    Stoffel M; Gianello P; Squifflet JP; Pirson Y; Alexandre GP
    Transplantation; 1988 Oct; 46(4):594-5. PubMed ID: 2845613
    [No Abstract]   [Full Text] [Related]  

  • 56. Ganciclovir for severe cytomegalovirus infection in transplant recipients.
    Rostoker G; Ben Maadi A; Buisson C; Deforge L; Weil B; Lang P
    Lancet; 1988 Nov; 2(8620):1137-8. PubMed ID: 2903346
    [No Abstract]   [Full Text] [Related]  

  • 57. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
    J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones CJ; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus prophylaxis in solid organ transplant recipients.
    Patel R; Snydman DR; Rubin RH; Ho M; Pescovitz M; Martin M; Paya CV
    Transplantation; 1996 May; 61(9):1279-89. PubMed ID: 8629285
    [No Abstract]   [Full Text] [Related]  

  • 60. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.